Ocugen licenses OCU400 retinitis pigmentosa gene therapy rights to Roots Pharmaceutical in MENA region

Bitget2026/10/14 10:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ocugen signed an exclusive MENA licensing deal with Roots Pharmaceutical for OCU400, its modifier gene therapy for retinitis pigmentosa.
Terms include an upfront license fee, up to $4 million in initial development payments, up to $255 million in sales milestones.
Ocugen will earn 22% royalties on OCU400 net sales in the region.
Commercial supply will be manufactured and supplied by Ocugen under a related supply agreement.
Phase 3 liMeliGhT topline data is expected in Q1 2027, ahead of planned U.S. and European filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140630PRIMZONEFULLFEED9845309) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ocugen licenses OCU400 retinitis pigmentosa gene therapy rights to Roots Pharmaceutical in MENA region

You may also like

Crypto prices